Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0003382 | Stomach | GC | epithelial cell morphogenesis | 8/1159 | 33/18723 | 7.27e-04 | 9.50e-03 | 8 |
GO:00085443 | Stomach | GC | epidermis development | 33/1159 | 324/18723 | 3.43e-03 | 2.96e-02 | 33 |
GO:00099134 | Stomach | GC | epidermal cell differentiation | 23/1159 | 202/18723 | 3.50e-03 | 3.02e-02 | 23 |
GO:000206411 | Stomach | CAG with IM | epithelial cell development | 29/1050 | 220/18723 | 1.64e-05 | 5.16e-04 | 29 |
GO:00033821 | Stomach | CAG with IM | epithelial cell morphogenesis | 7/1050 | 33/18723 | 2.02e-03 | 2.10e-02 | 7 |
GO:000991311 | Stomach | CAG with IM | epidermal cell differentiation | 22/1050 | 202/18723 | 2.23e-03 | 2.25e-02 | 22 |
GO:000854411 | Stomach | CAG with IM | epidermis development | 31/1050 | 324/18723 | 2.66e-03 | 2.58e-02 | 31 |
GO:000206421 | Stomach | CSG | epithelial cell development | 28/1034 | 220/18723 | 3.30e-05 | 9.05e-04 | 28 |
GO:00033822 | Stomach | CSG | epithelial cell morphogenesis | 7/1034 | 33/18723 | 1.85e-03 | 1.97e-02 | 7 |
GO:000854421 | Stomach | CSG | epidermis development | 30/1034 | 324/18723 | 3.99e-03 | 3.47e-02 | 30 |
GO:000991321 | Stomach | CSG | epidermal cell differentiation | 21/1034 | 202/18723 | 4.02e-03 | 3.48e-02 | 21 |
GO:0002064112 | Thyroid | PTC | epithelial cell development | 101/5968 | 220/18723 | 8.53e-06 | 9.74e-05 | 101 |
GO:006053719 | Thyroid | PTC | muscle tissue development | 156/5968 | 403/18723 | 1.98e-03 | 1.06e-02 | 156 |
GO:003434110 | Thyroid | PTC | response to interferon-gamma | 59/5968 | 141/18723 | 7.88e-03 | 3.33e-02 | 59 |
GO:00713468 | Thyroid | PTC | cellular response to interferon-gamma | 50/5968 | 118/18723 | 1.04e-02 | 4.19e-02 | 50 |
GO:001470617 | Thyroid | PTC | striated muscle tissue development | 144/5968 | 384/18723 | 1.05e-02 | 4.22e-02 | 144 |
GO:006053724 | Thyroid | ATC | muscle tissue development | 181/6293 | 403/18723 | 1.27e-06 | 1.62e-05 | 181 |
GO:001470622 | Thyroid | ATC | striated muscle tissue development | 168/6293 | 384/18723 | 1.91e-05 | 1.73e-04 | 168 |
GO:000206428 | Thyroid | ATC | epithelial cell development | 103/6293 | 220/18723 | 3.06e-05 | 2.55e-04 | 103 |
GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FLNB | SNV | Missense_Mutation | novel | c.1132G>A | p.Asp378Asn | p.D378N | O75369 | protein_coding | deleterious(0.03) | probably_damaging(0.924) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
FLNB | SNV | Missense_Mutation | novel | c.1797N>T | p.Gln599His | p.Q599H | O75369 | protein_coding | deleterious(0.01) | possibly_damaging(0.726) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
FLNB | SNV | Missense_Mutation | | c.1202N>A | p.Thr401Asn | p.T401N | O75369 | protein_coding | deleterious(0.02) | benign(0.03) | TCGA-A7-A26J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
FLNB | SNV | Missense_Mutation | rs144158201 | c.2035N>T | p.Pro679Ser | p.P679S | O75369 | protein_coding | tolerated(0.15) | benign(0.314) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
FLNB | SNV | Missense_Mutation | rs768998920 | c.163N>C | p.Glu55Gln | p.E55Q | O75369 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FLNB | SNV | Missense_Mutation | | c.2166G>C | p.Trp722Cys | p.W722C | O75369 | protein_coding | tolerated(0.1) | probably_damaging(0.997) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FLNB | SNV | Missense_Mutation | rs80356520 | c.4912C>G | p.Arg1638Gly | p.R1638G | O75369 | protein_coding | deleterious(0.02) | possibly_damaging(0.726) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
FLNB | SNV | Missense_Mutation | novel | c.6208N>T | p.Val2070Leu | p.V2070L | O75369 | protein_coding | deleterious(0.01) | possibly_damaging(0.626) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
FLNB | SNV | Missense_Mutation | novel | c.3056N>T | p.Thr1019Ile | p.T1019I | O75369 | protein_coding | deleterious(0.02) | possibly_damaging(0.673) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
FLNB | SNV | Missense_Mutation | rs142229998 | c.7462N>A | p.Gly2488Ser | p.G2488S | O75369 | protein_coding | deleterious(0.02) | probably_damaging(0.926) | TCGA-BH-A208-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |